Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases

By Cerchietti Leandro   Bonomi Marcelo   Navigante Alfredo   Castro Monica   Cabalar Maria   Roth Berta  

Journal of Neuro-Oncology, Vol. 71, Iss. 1, 2005-01 ,pp. : 73-81

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in medullary thyroid carcinoma

By              

Molecular Medicine Reports, Vol. 9, Iss. 2, 2014-01 ,pp. : 768-772

Spandidos Publications

Access to resources Recommend Favorite

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

By Coombes R. C.   Tat T.   Miller M. L.   Reise J. A.   Mansi J. L.   Hadjiminas D. J.   Shousha S.   Elsheikh S. E.   Lam E. W-F.   Horimoto Y.   El-Bahrawy M.   Aboagye E. O.   Contractor K. B.   Shaw J. A.   Walker R. A.   Marconell M. H.   Palmieri C.   Stebbing J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 924-930

Oxford University Press

Access to resources Recommend Favorite

Cyclo-Oxygenase-2 Inhibitors in Colorectal Cancer Prevention

By Moshkowitz Menachem   Arber Nadir  

American Journal of Cancer, Vol. 5, Iss. 6, 2006-01 ,pp. : 357-362

Adis International

Access to resources Recommend Favorite

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

By Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 429-437

Springer Publishing Company

Access to resources Recommend Favorite